APRI, the FIB-4 score, and Forn's index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 9, 2013, Pages 1076-1081

  Ucar, Fatma ^a   Sezer, Sevilay ^c   Ginis, Zeynep ^a   Ozturk, Gulfer ^a   Albayrak, Aynur ^b   Basar, Omer ^b   Ekiz, Fuat ^b   Coban, Sahin ^b   Yuksel, Osman ^b   Armutcu, Ferah ^d   Akbal, Erdem ^e  

^a MINISTRY OF HEALTH   (Turkey)

^b DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c Numune Training and Research Hospital   (Turkey)

^d FATIH UNIVERSITY   (Turkey)

^e ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

chronic hepatitis B; fibrosis; noninvasive; serum markers

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BILIRUBIN GLUCURONIDE; FETUIN A; FIBROBLAST GROWTH FACTOR 21; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX; BILIRUBIN BLOOD LEVEL; CALCULATION; CHRONIC HEPATITIS; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FIBROSIS INDEX; FORN INDEX; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; THROMBOCYTE; THROMBOCYTE COUNT;

ADULT; ALPHA-2-HS-GLYCOPROTEIN; AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BIOPSY; FEMALE; FIBROBLAST GROWTH FACTORS; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROGNOSIS; ROC CURVE; SEVERITY OF ILLNESS INDEX; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84881378339     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32835fd699     Document Type: Article

References (30)

1. Pungpapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc 2007; 82:967-975. (Pubitemid 47206372)
2. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539. (Pubitemid 46374607)
3. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48:335-352.
4. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357:1069-1075. (Pubitemid 32322537)
5. Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997; 145:1039-1047.
6. Hui AY, Chan HL, Wong VW, Liew CT, Chim AM, Chan FK, et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol 2005; 100:616-623. (Pubitemid 40487561)
7. Castera L, Negre I, Samii K, Buffet C. Pain experienced during percutaneous liver biopsy. Hepatology 1999; 30:1529-1530.
8. Kim BK, Kim HS, Park JY, Kim DY, Ahn SH, Chon CY, et al. Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B. PloS One 2012; 7:e41964.
9. Zarski JP, Sturm N, Guechot J, Paris A, Zafrani ES, Asselah T, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol 2012; 56:55-62.
10. Jarcuska P, Janicko M, Veseliny E, Jarcuska P, Skladany L. Circulating markers of liver fibrosis progression. Clinica Chimica Acta 2010; 411:1009-17.
11. Friedman SL. Liver fibrosis-from bench to bedside. J Hepatol 2003; 38 (Suppl 1):38-53.
12. Liu T, Wang X, Karsdal MA, Leeming DJ, Genovese F. Molecular serum markers of liver fibrosis. Biomark Insights 2012; 7:105-117.
13. Wang H, Lafdil F, Wang L, Yin S, Feng D, Gao B. Tissue inhibitor of metalloproteinase 1 (TIMP-1) deficiency exacerbates carbon tetrachlorideinduced liver injury and fibrosis in mice: involvement of hepatocyte STAT3 in TIMP-1 production. Cell Biosci 2011; 1:14.
14. Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med (Maywood) 2008; 233:109-122. (Pubitemid 351231543)
15. Flisiak R, Maxwell P, Prokopowicz D, Timms PM, Panasiuk A. Plasma tissue inhibitor of metalloproteinases-1 and transforming growth factor beta 1-possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis. Hepatogastroenterology 2002; 49:1369-1372.
16. Overall CM, Wrana JL, Sodek J. Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J Biol Chem 1991; 266:14064-14071. (Pubitemid 21907461)
17. Boeker KHW, Haberkorn CI, Michels D, Flemming P, Manns MP, Lichtinghagen R. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta 2002; 316:71-81. (Pubitemid 34028190)
18. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112:357-366. (Pubitemid 38063764)
19. Demetriou M, Binkert C, Sukhu B, Tenenbaum HC, Dennis JW. Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem 1996; 271: 12755-12761. (Pubitemid 26175845)
20. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-526. (Pubitemid 36919874)
21. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-1325. (Pubitemid 43980111)
22. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-992.
23. Bedossa P, Potnard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293. (Pubitemid 26260021)
24. Gumusay O, Ozenirler S, Atak A, Sonmez C, Ozkan S, Tuncel AF, et al. Diagnostic potential of serum direct markers and non-invasive fibrosis models in patients with chronic hepatitis B. Hepatol Res 2012 . doi: 10.1111/j.1872-034X. 2012.01057.
25. Zhu CL, Li WT, Li Y, Gao RT. Serum levels of tissue inhibitor of metalloproteinase-1 are correlated with liver fibrosis in patients with chronic hepatitis B. J Dig Dis 2012; 13:558-563.
26. Larrousse M, Laguno M, Segarra M, De Lazzari E, Martinez E, Blanco JL, et al. Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2007; 46:304-311. (Pubitemid 350287357)
27. Mallet V, Dhalluin-Venier V, Roussin C, Bourliere M, Pettinelli ME, Giry C, et al. The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2009; 29:409-415.
28. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7:1104-1112.
29. Kanzler S, Baumann M, Schirmacher P, Dries V, Bayer E, Gerken G, et al. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat 2001; 8:430-437. (Pubitemid 35013568)
30. Mahmoud AA, Bakir AS, Shabana SS. Serum TGF-b, serum MMP-1, and HOMA-IR as non-invasive predictors of fibrosis in Egyptian patients with NAFLD. Saudi J Gastroenterol 2012; 18:327-333.